دفاع دارویی در برابر تهدیدات CBRN: مروری از مکانیسم‌ها تا مهم‌ترین اقدامات متقابل پزشکی

1.    Reddy DS. Progress and challenges in developing medical countermeasures for chemical, biological, radiological, and nuclear threat agents. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):260-7. doi:10.1124/jpet.123.002040
   2.    Bland SA. Chemical, Biological, Radiological and Nuclear (CBRN) casualty management principles.  Conflict and Catastrophe Medicine: A Practical Guide: Springer; 2013. pp. 747-70. doi:10.1007/ 978-1-4471-2927-1_46 
   3.    Kako M, Hammad K, Mitani S, Arbon P. Existing approaches to chemical, biological, radiological, and nuclear (CBRN) education and training for health professionals: findings from an integrative literature review. Prehospital and Disaster Medicine. 2018; 33(2):182-90. doi:10.1017/S1049023X18000043 
   4.    Richardt A, Hülseweh B, Niemeyer B, Sabath F. CBRN protection: managing the threat of chemical, biological, radioactive and nuclear weapons: John Wiley & Sons; 2012. doi:10.1002/9783527650163  
   5.    Econdi S, Marchesi S, Bisio C, Guidotti M. Dual-Use Chemicals. Spectrum of Dual-Use Technologies: Unforeseen Risks Versus Returns: Springer; 2025. pp. 63-109. doi:10.1007/978-3-032-00202-0_3 
   6.    Tin D, Cheng L, Shin H, Hata R, Granholm F, Braitberg G, et al. A descriptive analysis of the use of chemical, biological, radiological, and nuclear weapons by violent non-state actors and the modern-day environment of threat. Prehospital and Disaster Medicine. 2023;38(3):395-400. doi:10.1017/s10 49023x23000481 
   7.    Malizia A, McGovern J, Sarigiannis D, Karakitsios S, Anastas PT, Ludovici GM, et al. Integrating the exposome framework in CBRNe risk assessment: a holistic approach to chemical, biological, radiological, nuclear, and explosive threats. The European Physical Journal Plus. 2025;140(11): 1103. doi:10.1140/epjp/s13360-025-07030-4 
   8.    Coleman CN, Bader JL, Koerner JF, Hrdina C, Cliffer KD, Hick JL, et al. Chemical, biological, radiological, nuclear, and explosive (CBRNE) science and the CBRNE science medical operations science support expert (CMOSSE). Disaster Medicine and Public Health Preparedness. 2019;13(5-6):995-1010. doi:10.1017/dmp.2018.163 
   9.    Geoghegan J, Tong JL. Chemical warfare agents. Continuing Education in Anaesthesia, Critical Care & Pain. 2006;6(6):230-4. doi:10.1093/bjaceaccp/ mkl052 
   10.    Ganesan K, Raza S, Vijayaraghavan R. Chemical warfare agents. Journal of Pharmacy and Bioallied Sciences. 2010;2(3):166-78. doi:10.4103/0975-7406.68498 
   11.    R Co, Chemical DNfICMRt, Incidents BT. Chemical and biological terrorism: research and development to improve civilian medical response: National Academies Press; 1999. doi:10.10 16/s0736-4679(99)00168-7 
   12.    Labaška M, Gál M, Mackuľak T, Švorec J, Kučera J, Helenin J, et al. Neutralizing the threat: A comprehensive review of chemical warfare agent decontamination strategies. Journal of Environmental Chemical Engineering. 2024;12(6): 114243. doi:10.1016/j.jece.2024.114243 
   13.    Rathish B, Pillay R, Wilson A, Pillay VV. Comprehensive review of bioterrorism. 2021.
   14.    Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nature Reviews Drug Discovery. 2005;4(4):281-96. doi:10.10 38/nrd1694 
   15.    Green MS, LeDuc J, Cohen D, Franz DR. Confronting the threat of bioterrorism: realities, challenges, and defensive strategies. The Lancet Infectious Diseases. 2019;19(1):e2-e13. doi:10.10 16/s1473-3099(18)30298-6 
   16.    Kosti O. Long-Term Health Monitoring of Populations Following a Nuclear or Radiological Incident in the United States: Proceedings of a Workshop. 2019. doi:10.17226/25443 
   17.    Alrusayni YA, Alkhattabi E. Dirty Bomb (Radiological Dispersal Device).  Ciottone's Disaster Medicine: Elsevier; 2024. pp. 498-501. doi:10.1016/b978-0-323-80932-0.00080-x 
   18.    Obrador E, Salvador-Palmer R, Villaescusa JI, Gallego E, Pellicer B, Estrela JM, et al. Nuclear and radiological emergencies: biological effects, countermeasures and biodosimetry. Antioxidants. 2022;11(6):1098. doi:10.3390/antiox11061098 
   19.    Wagner RH, Boles MA, Henkin RE. Treatment of radiation exposure and contamination. Radiographics. 1994;14(2):387-96. doi:10.1148/radiographics.14. 2.8190961 
   20.    Bajgar J. Laboratory examination in nerve agent intoxication. Acta Medica. 2015;56(3):89-96. doi:10.14712/18059694.2014.15 
   21.    Parry S, Johnson C. Chemical, biological, radiological and nuclear major incidents. Surgery. 2024;42(7):487-93. doi:10.1016/j.mpsur.2024.03.0 15 
   22.    Rastogi M, Singh SK. Advances in Molecular Diagnostic Approaches for Biothreat Agents. In: Singh SK, Kuhn JH, editors. Defense Against Biological Attacks: Volume II. Cham: Springer International Publishing; 2019. pp. 281-310. doi:10.1007/978-3-030-03071-1_13 
   23.    Neumeister SM, Gray JP. The Strategic National Stockpile: identification, support, and acquisition of medical countermeasures for CBRN incidents. Toxicology Mechanisms and Methods. 2021; 31(4):308-21. doi:10.1080/15376516.2020.1853294

24.    Singh VK, Romaine PL, Newman VL, Seed TM. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents. Expert Opinion on Therapeutic Patents. 2016; 26(12):1399-408. doi:10.1080/13543776.2016.1231805 
25.    Singh VK, Garcia M, Wise SY, Seed TM. Medical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents. Expert Opinion on Therapeutic Patents. 2016;26(12):1431-47. doi:10.1080/13543776.2017.1233178 
26.    Moshiri M, Darchini-Maragheh E, Balali-Mood M. Advances in toxicology and medical treatment of chemical warfare nerve agents. DARU Journal of Pharmaceutical Sciences. 2012;20(1):81. doi:10.1 186/2008-2231-20-81 
27.    Vijayaraghavan R. Autoinjector device for rapid administration of drugs and antidotes in emergency situations and in mass casualty management. Journal of International Medical Research. 2020;48(5): 0300060520926019. doi:10.1177/030006052092 6019 
28.    Noga M, Michalska A, Jurowski K. Review of possible therapies in treatment of Novichoks poisoning and HAZMAT/CBRNE approaches: state of the art. Journal of Clinical Medicine. 2023; 12(6):2221. doi:10.3390/jcm12062221 
29.    Christensen DR, Hartman LJ, Loveless BM, Frye MS, Shipley MA, Bridge DL, et al. Detection of biological threat agents by real-time PCR: comparison of assay performance on the RAPID, the LightCycler, and the Smart Cycler platforms. Clinical Chemistry. 2006;52(1):141-5. doi:10.13 73/clinchem.2005.052522 
30.    Oostrom-Shah L. Chemical, Biological, Radiological, and Nuclear Quarantine. Ciottone's Disaster Medicine: Elsevier; 2024. pp. 537-44. doi:10.1016/b978-0-323-80932-0.00085-9 
31.    Ballard DH, Dang AJ, Kumfer BM, Weisensee PB, Meacham JM, Scott AR, et al. Protection levels of N95-level respirator substitutes proposed during the COVID-19 pandemic: safety concerns and quantitative evaluation procedures. BMJ Open. 2021;11(9):e045557. doi:10.1136/bmjopen-2020-045557 
32.    Soyege OS, Nwokedi CN, Tomoh BO, Mustapha AY, Mbata AO, Balogun OD, et al. Public health crisis management and emergency preparedness: Strengthening healthcare infrastructure against pandemics and bioterrorism threats. Journal of Frontiers in Multidisciplinary Research. 2024; 5(2):52-68. doi:10.54660/.ijfmr.2024.5.2.52-68 
33.    Wolbarst AB, Wiley Jr AL, Nemhauser JB, Christensen DM, Hendee WR. Medical response to a major radiologic emergency: a primer for medical and public health practitioners. Radiology. 2010;254(3):660-77. doi:10.1148/radiol.09090330 
34.    Kasper K. Time, distance, shielding, and radioprotectants. Health Physics. 2004;87(1):1-2. doi:10.1097/00004032-200407000-00001 
35.    Izrael YA. Radioactive fallout after nuclear explosions and accidents: Elsevier; 2002. doi:10.1016/s1569-4860(02)80022-5 
36.    Council NR, Earth Do, Studies L, Research BoRE, Distribution CtAt, Incident AoPIitEoaN. Distribution and administration of potassium iodide in the event of a nuclear incident: National Academies Press; 2004. doi:10.17226/10868 
37.    Rahman MS, Rifat H, Jahid M. Disaster Management Strategies Before, During and in the Aftermath of a Nuclear Explosion. Jahid, Disaster Management Strategies Before, During and in the Aftermath of a Nuclear Explosion (May 19, 2024). 2024. doi:10.2139/ssrn.4833515 
38.    Yamaguchi M, Kashiwakura I. The acute radiation syndrome-mitigator romiplostim and secreted extracellular vesicles improved survival in mice acutely exposed to myelosuppressive doses of ionizing radiation. Biomolecules. 2023;13(5):837. doi:10.3390/biom13050837 
39.    Harrold J, Gisleskog PO, Perez‐Ruixo JJ, Delor I, Chow A, Jacqmin P, et al. Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome. Clinical and Translational Science. 2020;13(4):807-17.
40.    Hunter KS, Carnell LS, DiCarlo AL, Hoffman CM, Loelius SG, Homer M. Interagency approaches to animal models for acute radiation exposure. International Journal of Radiation Biology. 2021;97 (sup1):S2-5. doi:10.1080/09553002.2021.2002661 
41.    Maurin M. Francisella tularensis as a potential agent of bioterrorism?. Expert Review of Anti-Infective Therapy. 2015;13(2):141-4. doi:10.1586/14787210.2015.986463 
42.    Oyston PC, Sjöstedt A, Titball RW. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nature Reviews Microbiology. 2004;2(12):967-78. doi:10.1038/nrmicro1045 
43.    Pohanka M. Bacillus anthracis as a biological warfare agent: infection, diagnosis and countermeasures. Bratislava Medical Journal. 2020;121(3):175-81. doi:10.4149/bll_2020_026 
44.    Ashiq HT, Khan B, Anjum A, Sultan R, Zaib W, Ashiq M, et al. Bacillus Anthracis: A Bioterrorism Agent. One Health Triad. Unique Scientific Publishers, Faisalabad, Pakistan. 2023;2:34-40. doi:10.47278/book.oht/2023.38 
45.    Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. Indian Journal of Medical Research. 2010;132(5):489-503.

46.    Adler M, Franz DR. Toxicity of botulinum neurotoxin by inhalation: implications in bioterrorism. 2016. doi:10.1039/9781849737913-00167  
47.    Dorner BG, Zeleny R, Harju K, Hennekinne JA, Vanninen P, Schimmel H, et al. Biological toxins of potential bioterrorism risk: Current status of detection and identification technology. TrAC Trends in Analytical Chemistry. 2016;85:89-102.  doi:10.1016/j.trac.2016.05.024  
48.    Domashevskiy AV. Forensic Files: Ricin Toxin, a Category B Bioterrorism Agent. Journal of Forensic Legal & Investigative Sciences. 2016;2(010). doi:10.24966/flis-733x/100010  
49.    Chai PR, Hayes BD, Erickson TB, Boyer EW. Novichok agents: a historical, current, and toxicological perspective. Toxicology Communications. 2018;2(1):45-8.
50.    Voiţă-Mekereş F, Delcea C, Buhaș CL, Ciocan V. Novichok toxicology: A review study. Archives of Pharmacy Practice. 2023;14(3-2023):62-6. doi:10.5 1847/4f46g0066j  
51.    Pampalakis G, Kostoudi S. Chemical, physical, and toxicological properties of V-agents. International Journal of Molecular Sciences. 2023;24(10):8600. doi:10.3390/ijms24108600 
52.    Vale A, Marrs TC, Rice P. Chemical terrorism and nerve agents. Medicine. 2012;40(2):77-9. doi:10.1016/j.mpmed.2011.11.017 
53.    Tu A. Chemical Agents and Weapons. Chemical and Biological Weapons and Terrorism: CRC Press; 2017. pp. 3-24. doi:10.1201/9781315305516-1 
54.    Wattana M, Bey T. Mustard gas or sulfur mustard: an old chemical agent as a new terrorist threat. Prehospital and Disaster Medicine. 2009;24(1):19-29. doi:10.1017/s1049023x0000649x 
55.    Saladi R, Smith E, Persaud A. Mustard: a potential agent of chemical warfare and terrorism. Clinical and Experimental Dermatology. 2006;31(1):1-5. doi:10.1111/j.1365-2230.2005.01945.x 
56.    Radke B, Jewell L, Piketh S, Namieśnik J. Arsenic-based warfare agents: production, use, and destruction. Critical Reviews in Environmental Science and Technology. 2014;44(14):1525-76. doi:10.1080/10643389.2013.782170 
57.    Sammarco DA. Chemical and biological agents of war: Concept, cause, care. Drug Topics. 2002;146 (2):55.
58.    Henretig FM. Preparation for terrorist threats: biologic and chemical agents. Clinical Pediatric Emergency Medicine. 2009;10(3):130-5. doi:10.10 16/j.cpem.2009.07.006 
59.    Givens ML. Phosgene and toxic gases. Medical Response to Terrorism: Preparedness and Clinical Practice. 2005:38. doi:10.1007/978-1-4615-5285-7_49 
60.    Fernando DM, De Alwis LB. Chemical and Biological Warfare. Sri Lanka Journal of Forensic Medicine, Science & Law. 2011;1(2). doi:10.40 38/sljfmsl.v1i2.2720 
61.    Dereli C, Dağlıoğlu N. Fentanyl and fentanyl subgroups as chemical weapons. Hacettepe Journal of Biology and Chemistry. 2024;52(5):363-72.
62.    Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiation Research. 2008;170(4):540-8. doi:10.1667/rr1485.1 
63.    Mishra V, Nair S. Decorporation of radionuclides. InHandbook on Radiation Environment, Volume 2: Dose Measurements. Singapore: Springer Nature Singapore. 2024. pp. 725-761. doi:10.1007/978-981-97-2799-5_25 
64.    Donnelly EH, Nemhauser JB, Smith JM, Kazzi ZN, Farfan EB, Chang AS, et al. Acute radiation syndrome: assessment and management. Southern Medical Journal. 2010;103(6):541. doi:10.1097/ smj.0b013e3181ddd571 
65.    Reeves G. Overview of use of G-CSF and GM-CSF in the treatment of acute radiation injury. Health Physics. 2014;106(6):699-703. doi:10.1097/hp.000 0000000000090 
66.    Masson P, Lushchekina SV. Emergence of catalytic bioscavengers against organophosphorus agents. Chemico-Biological Interactions. 2016;259:319-26. doi:10.1016/j.cbi.2016.02.010 
67.    Prchalova E, Kohoutova Z, Knittelova K, Malinak D, Musilek K. Strategies for enhanced bioavailability of oxime reactivators in the central nervous system. Archives of Toxicology. 2023; 97(11):2839-60. doi:10.1007/s00204-023-03587-0 
68.    Wiaderek B, Wiśnik-Sawka M, Gajda D, Rzadkowska K, Bryczek-Wrobel P, Sałaciński T. 4th generation of warfare agents–Novichoks: threats, problems, challenges for the security of the armed forces and civilian population. Food and Chemical Toxicology. 2025;200:115371. doi:10.10 16/j.fct.2025.115371 
69.    da Fonseca Carvalho LM. Novichok (s) a challenge to the chemical weapons convention. Port J Mil Sci. 2021;9:39-62. doi:10.31482/mmsl.2018.012 
70.    Clark DP, Pazdernik NJ. Biological warfare: infectious disease and bioterrorism. Biotechnology. 2015:687. doi:10.1016/b978-0-12-385015-7.00022-3 
71.    Hu WG, Nagata L. Opportunities and challenges of therapeutic monoclonal antibodies as medical countermeasures for biodefense. Journal of Bioterrorism and Biodefense. 2016;7:1000149. doi:10.4172/2157-2526.1000149 
72.    Nijnik A. Immunomodulatory approaches for prevention and treatment of infectious diseases. Current Opinion in Microbiology. 2013;16(5):590-5. doi:10.1016/j.mib.2013.06.011 

73.    McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochemical Pharmacology. 2014;87(1):162-71. doi:10.1016/j.bcp.2013.08.006 
74.    Göransson Nyberg A, Stricklin D, Sellström Å. Mass casualties and health care following the release of toxic chemicals or radioactive material—contribution of modern biotechnology. International Journal of Environmental Research and Public Health. 2011;8(12):4521-49. doi:10.3390/ijerph 8124521 
75.    Arnautou P, Garnier G, Maillot J, Konopacki J, Brachet M, Bonnin A, et al. Management of acute radiation syndrome. Transfusion Clinique Et Biologique. 2024;31(4):253-9. doi:10.1016/j.tracli. 2024.07.002 
76.    Ben Ouagrham-Gormley S, Fye-Marnien SR. Is CRISPR a security threat?. InDefense Against Biological Attacks: Volume I. Cham: Springer International Publishing. 2019. pp. 233-251. doi:10.1007/978-3-030-03053-7_12